泌尿生殖系统肿瘤免疫治疗的临床研究进展  

Clinical Research Advances in Immunotherapy for Urogenital Tumor

作　　者：欧武陵[1] 蔡茜 胡胜[1] 董爽[1] OU Wuling;CAI Qian;HU Sheng;DONG Shuang(Department of Thoracic Oncology,Hubei Cancer Hospital,Wuhan 430079,China)

机构地区：[1]湖北省肿瘤医院胸部肿瘤内科,武汉430079

出　　处：《医药导报》2020年第10期1384-1389,共6页Herald of Medicine

摘　　要：随着免疫治疗研究的深入,其在泌尿生殖系统肿瘤治疗中的地位越来越高。临床上目前已经有多个疫苗和免疫检查点抑制剂获批用于前列腺癌、肾癌和尿路上皮癌等多种泌尿生殖系统肿瘤的二线治疗。此外,还有许多正在进行的临床试验旨在探索免疫疗法与其他类型药物的联合应用,预测肿瘤免疫治疗疗效的标志物,以及免疫检查点抑制剂在一线、辅助治疗中的作用价值,以进一步提高免疫治疗的有效性和准确性,并扩大受益人群。该文从前列腺癌、肾癌和尿路上皮癌3种不同类型的泌尿生殖系统肿瘤出发,围绕肿瘤疫苗、免疫检查点抑制剂等治疗手段,总结免疫疗法在泌尿生殖系统肿瘤中的临床应用,并对其未来的治疗潜力进行讨论。The advent of immunotherapy has led to significant changes in the treatment landscape of urogenital tumors.Currently,a number of vaccines and immunosuppressive checkpoint inhibitors,such as drugs targeting the programmed death 1(PD-1),and cytotoxic T-lymphocyte associated antigen(CTLA-4),have been approved for the second-line treatment of a variety of urogenital tumors,including prostate cancer,renal cell carcinoma,and urothelial carcinoma.In addition,there are many ongoing clinical trials aiming at exploring the combined use of immunotherapy and other types of drugs,and biomarkers for predicting the efficacy of tumor immunotherapy.And the role of immune checkpoint inhibitors in first-line and adjuvant treatment were also investigated so as to further improve the effectiveness and accuracy of immunotherapy and expand the beneficiary population.In this review,we summarize the clinical application of immunotherapy in urogenital system tumors,including three different types of urogenital tumors:prostate cancer,renal cancer and urothelial cancer.In addition,perspectives on the future use of checkpoint inhibitors are discussed,including the potential use in combination with other agents,and the identification of biomarkers to guide patient selection and individualization of therapy.

关 键 词：泌尿生殖系统肿瘤 免疫治疗 免疫检查点抑制剂 疫苗 

分 类 号：R979.5[医药卫生—药品] R737[医药卫生—药学]